ATAI
ATAI Life Sciences BV
NASDAQ: ATAI · HEALTHCARE · BIOTECHNOLOGY
$4.12
-4.85% today
Updated 2026-04-29
Market cap
$1.51B
P/E ratio
—
P/S ratio
369.70x
EPS (TTM)
$-2.91
Dividend yield
—
52W range
$1 – $7
Volume
6.2M
ATAI Life Sciences BV (ATAI) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $19.88M | $20.38M | $233000.00 | $314000.00 | $308000.00 | $4.09M |
| Revenue growth (YoY) | — | — | +2.5% | -98.9% | +34.8% | -1.9% | +1227.6% |
| Cost of revenue | $6000.00 | $24000.00 | $47000.00 | $168000.00 | $319000.00 | $473000.00 | $1.01M |
| Gross profit | $-6000.00 | $-24000.00 | $20.38M | $233000.00 | $314000.00 | $308000.00 | $3.08M |
| Gross margin | — | -0.1% | 100.0% | 100.0% | 100.0% | 100.0% | 75.3% |
| R&D | $12.76M | $23.43M | $47.96M | $74.31M | $62.20M | $55.45M | $53.06M |
| SG&A | $5.09M | $80.73M | $92.75M | $70.35M | $63.58M | $47.54M | $65.09M |
| Operating income | $-17.85M | $-104.16M | $-135.81M | $-144.79M | $-125.47M | $-102.69M | $-114.06M |
| Operating margin | — | -524.0% | -666.5% | -62140.3% | -39958.9% | -33341.2% | -2789.5% |
| EBITDA | $-17.47M | $-92.12M | $-120.28M | $-134.09M | $-36.31M | $-144.81M | $-113.05M |
| EBITDA margin | — | -463.4% | -590.3% | -57549.8% | -11564.0% | -47015.6% | -2764.7% |
| EBIT | $-17.47M | $-92.14M | $-120.33M | $-134.26M | $-36.63M | $-145.28M | $-114.06M |
| Interest expense | $15.71M | $71.05M | $66.91M | $923000.00 | $2.66M | $3.12M | $1.16M |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-14.14M | $-169.84M | $-167.81M | $-152.38M | $-40.22M | $-149.27M | $-660.05M |
| Net income growth (YoY) | — | -1101.3% | +1.2% | +9.2% | +73.6% | -271.1% | -342.2% |
| Profit margin | — | -854.3% | -823.6% | -65401.3% | -12810.2% | -48464.0% | -16142.0% |